ArticleCardiovascular and interventional radiology2026
Effectiveness of Real-Time CT/MRI-US Fusion Imaging in Thermal Ablation of Ultrasonographically Inconspicuous Hepatocellular Carcinoma.
Article in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aims to compare local recurrence-free survival (LRFS) in patients with de novo HCC treated with thermal ablation (TA) using real-time CT/MRI-US fusion imaging (FI) or ultrasound (US) for needle placement. MATERIALS AND
methodsThis single-center retrospective cohort study included patients with de novo HCC who underwent percutaneous TA between January 2013 and December 2021. US was the preferred image guidance modality for ultrasonographically conspicuous lesions; however, for inconspicuous lesions, FI (US-CT or US-MRI) was used for needle placement. Propensity score matching (PSM) with a 1:1 ratio was applied to balance baseline variables between the US- and FI-guided groups. LRFS, disease-free survival (DFS), and overall survival (OS) were compared before and after matching using the log-rank test. Univariate analyses using Cox regression were used to identify prognostic factors for LRFS.
resultsA total of 117 patients with 157 lesions were ablated using US and FI needle guidance in 100 and 57 tumors, respectively. PSM yielded 40 tumors in both groups. The 1-year LRFS rates were similar across the groups before and after matching (US: 0.82, FI: 0.94 (p = 0.07) and US: 0.87, FI: 0.91 (p = 0.20), respectively). Univariate analysis revealed that only tumor size was a predictive factor for LRFS. Before and after matching, the DFS and OS did not significantly differ between the groups (p > 0.05).
conclusionFI-guided needle placement facilitates effective targeting of HCC lesions that are ultrasonographically inconspicuous, yielding LRFS outcomes comparable to those achieved with US guidance for ultrasonographically conspicuous lesions. Level of Evidence 3b, Retrospective Cohort Study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.